| Symbol | PBMWW |
|---|---|
| Name | PSYENCE BIOMEDICAL LTD. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 121 RICHMOND STREET WEST PENTHOUSE, TORONTO, None None |
| Telephone | 27744604171 |
| Fax | — |
| — | |
| Website | https://www.psyence.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001985062 |
| Description | Psyence Biomedical Ltd. (Nasdaq: PBM) is the worlds first life science biotechnology company focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. The name Psyence combines the words psychedelics and science to affirm Psyence Biomeds commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. The Company is initially focused on mental health disorders in the context of Palliative Care. Additional info from NASDAQ: |
New Form EFFECT - PSYENCE BIOMEDICAL LTD. <b>Filed:</b> 2026-09-01 <b>AccNo:</b> 9999999995-26-002862 <b>Size:</b> 1 KB
Read morePsyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
Read moreNew Form SCHEDULE 13G/A - PSYENCE BIOMEDICAL LTD. <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001376474-26-000435 <b>Size:</b> 6 KB
Read moreNew Form SCHEDULE 13D - PSYENCE BIOMEDICAL LTD. <b>Filed:</b> 2026-06-03 <b>AccNo:</b> 0001213900-26-064484 <b>Size:</b> 17 KB
Read morePsyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Read morePsyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Read morePsyence BioMed Positioned as Worlds only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Read more